News Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Staff September 11, 2023 Iframe sync Post navigation Previous: Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research ConferenceNext: Major shareholder announcement – BlackRock, Inc. More Stories Healthcare News Robotics Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed Staff December 19, 2025 News Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase Staff December 19, 2025 Cancer News Pharmaceutical IMG Saxony-Anhalt: 2026 in Sight – Saxony-Anhalt Sets the Pace for Future Industries Staff December 19, 2025
